- Home
- NRIX vs OLN Comparison
NRIX vs OLN Comparison
Compare NRIX & OLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRIX | OLN |
|---|---|---|
| Founded | 2009 | 1892 |
| Country | United States | United States |
| Employees | 357 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | NRIX | OLN |
|---|---|---|
| Price | $23.38 | $23.20 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 13 |
| Target Price | ★ $30.50 | $25.23 |
| AVG Volume (30 Days) | 1.6M | ★ 3.2M |
| Earning Date | 04-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 2.92% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $76,987,000.00 | ★ $6,780,800,000.00 |
| Revenue This Year | N/A | $2.57 |
| Revenue Next Year | $48.05 | $3.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 99.31 | 3.68 |
| 52 Week Low | $8.20 | $18.08 |
| 52 Week High | $25.09 | $30.46 |
Technical Indicators
Market Signals| Indicator | NRIX | OLN |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 57.30 |
| Support Level | $14.63 | $22.98 |
| Resistance Level | $24.98 | $24.83 |
| Average True Range (ATR) | 1.21 | 0.98 |
| MACD | -0.26 | 0.50 |
| Stochastic Oscillator | 52.40 | 73.56 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About OLN Olin Corporation
Olin was founded in 1892 and has been publicly listed since 1917. The company has a unique dual identity compared with some of its chemical peers: it is the world's largest chlor-alkali producer by capacity, and it owns the Winchester brand, a leading US ammunition manufacturer. Olin has three reportable segments: chlor-alkali products and vinyls (CAPV or CAP), Epoxies, and Winchester, which represent around 55%, 20%, and 25% of sales, respectively.